Sign up Australia
Proactive Investors - Run By Investors For Investors

Zelda Therapeutics trade higher on medical cannabis focus

Shares have nearly tripled since the reverse takeover in late 2016.
Zelda Therapeutics trade higher on medical cannabis focus
The company has a solid pipeline of news flow in 2017

Zelda Therapeutics (ASX:ZLD) shares have continued their strong run in 2017 trading up over 85% year to date to $0.074.

This also means that the medical cannabis company’s share price has nearly tripled since listing on the Australian Stock Exchange in November, 2016 at $0.025.

Zelda is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis.

This human data has been generated over several years by a California-based group that has a high profile within the U.S. and a growing international profile.

Zelda has embarked on a program of human clinical trials initially in sleep disorder (insomnia) and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer.

The company expects to be commencing these trials during 2017 and have identified a relatively rapid path to commercialisation.

If successful, this could see Zelda obtaining product registrations in selected markets in 2018 with revenues flowing from there.





Register here to be notified of future ZLD Company articles
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

viagra.jpg
May 31 2017
Written responses from America’s Food & Drug Administration and the Medicines & Healthcare products Regulatory Agency (MHRA) here in Britain support its timeline, which sees marketing approval for the product in the second-quarter of 2019.
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.
Knee surgery
February 02 2017
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use